Literature DB >> 35845176

Acute Coronary Artery Occlusion during Transcatheter Aortic Valve Replacement in a Patient with an Anomalous Left Circumflex Coronary Artery.

Rongfeng Xu1, Jiandong Ding1, Lijuan Chen1, Yi Feng1, Genshan Ma1.   

Abstract

Background: Acute coronary artery occlusion (CAO) during transcatheter aortic valve replacement (TAVR) is a rare but life-threatening complication during the procedure; there were a few case reports about an anomalous LCX during perioperative period. We report a case of successful coronary protection using the chimney stenting technique in a patient with a severely calcified aortic valve and an anomalous LCX. Case Summary. A 75-year-old man was found an anomalous left circumflex coronary artery (LCX) originating from the right coronary cusp with severely calcified aortic valve stenosis requiring TAVR. When a self-expanding aortic valve was deployed, we found flow compromise in the right coronary system and circumflex to TIMI-0 flow. By using the chimney stenting technique, we rapidly planted 2 stents from the proximal CX branch to the sinotubular junction and the coronary flow was maintained.
Conclusion: Chimney stenting protection as a bailout technique is safe and feasible and should be considered in patients deemed to be at high risk of coronary flow compromise, especially with an anomalous LCX.
Copyright © 2022 Rongfeng Xu et al.

Entities:  

Year:  2022        PMID: 35845176      PMCID: PMC9286928          DOI: 10.1155/2022/6257367

Source DB:  PubMed          Journal:  Case Rep Cardiol        ISSN: 2090-6404


1. Introduction

Although traditional surgical aortic valve replacement (SAVR) has been the mainstream treatment method for symptomatic severe aortic stenosis, transcatheter aortic valve replacement (TAVR) is becoming a standard-of-care procedure for those patients who would be at high or intermediate risk for cardiac surgery. Acute coronary artery occlusion (CAO) during TAVR is a rare (<1%) but life-threatening complication in contemporary practice, and specific subsets of patients remain at risk [1]. Displacement of the calcified native valve leaflet over the coronary ostium and direct occlusion of the coronary ostium by the covered skirt of the transcatheter aortic prosthesis are the usual causes of CAO. This phenomenon is associated with anatomical factors, including lower-lying coronary ostia and shallow sinuses of Valsalva (SOVs), and especially valve-in-valve (VIV) for surgical bioprostheses [2]. Furthermore, an anomalous coronary artery may be an unusual cause of CAO [3]. There are only a few reports of TAVR in the context of an anomalous LCX [4]. Coronary protection during TAVR is a preemptive technique recommended in certain cases to avoid this complication. As an important bailout technique, the “chimney” stenting technique is performed during or after TAVR if coronary blood flow is compromised [5]. We report a case of successful coronary protection by using the chimney stenting technique in a patient with a severely calcified aortic valve and an anomalous LCX.

2. Case Presentation

A 75-year-old man was admitted to our hospital with a history of active dyspnea for 1 year and no coronary heart disease, hypertension, or diabetes. He had been smoking for 40 years, with 10 cigarettes per day. Physical exam revealed a grade 5 crescendo-decrescendo murmur without elevated JVP and lower extremity edema. Laboratory findings were pertinent for creatinine NT pro-BNP of 2320 pg/ml and TNI 0.023 ng/ml. The rest of his physical exam and laboratory was normal. Electrocardiogram showed a normal sinus rhythm with a known right bundle branch block. Echocardiogram demonstrated severe aortic stenosis with a mean aortic valve pressure gradient of 100.5 mmHg and peak velocity of 5.60 m/s, with preserved systolic function. The patient received intravenous diuretics with some clinical improvement. He was seen and evaluated by a cardiothoracic surgeon for evaluation of aortic valve replacement but deemed intermediate risk for SAVR, with an estimated surgical mortality risk of 4.15% according to the Society of Thoracic Surgeons score. Cardiac computed tomography angiography was performed as part of the TAVR evaluation (Figures 1(a)–1(d)) and showed severely calcified aortic leaflets with an anomalous LCX, which revealed a circumflex branch originating from the right SOV. The ostial heights of the left and right coronaries were 12.3 mm and 17.4 mm, respectively (Figures 1(e) and 1(f)), while the ostial height of the circumflex artery was 11.4 mm (Figure 1(g)). Coronary angiography revealed normal left and right coronary arteries and an anomalous circumflex coronary artery without stenosis (Figure 1(h)). Special attention was given to right coronary leaflet calcification and anatomical abnormalities of the circumflex. The decision was then made to proceed with TAVR utilizing the coronary protection technique during the procedure. TAVR was then undertaken from the right femoral artery through a 19F arterial sheath. With rapid ventricular pacing over a temporary transvenous pacing wire (180 bpm), balloon aortic valvuloplasty using a 22 × 40 mm balloon (VENUS MEDTECH, Hangzhou, China) with simultaneous root aortography was performed. There was flow compromise in the right coronary artery and circumflex to TIMI-0 flow (Figure 2(a)). To perform the coronary protection technique to avoid CAO, a 6F JR-4 guide catheter inserted through a transradial access was used to engage the anomalous LCX, and a guiding wire of 0.014 inches was advanced to the CX arteries with a 2.0 × 20 mm semicompliant balloon (Figure 2(b)). A 26 mm Venus-A self-expanding valve (VENUS MEDTECH, Hangzhou, China) with rapid ventricular pacing was then deployed. The position of the valve and function were confirmed by aortography and transesophageal echocardiography (TEE). We found flow compromise in the right coronary system and circumflex to TIMI-0 flow (Figure 2(c)), and the ST segments in the EKG were elevated. One drug-eluting stent (2.75 × 23 mm) was deployed from the proximal CX branch to the ostium, followed by deployment of another drug-eluting stent (3.0 × 18 mm) from the ostium of CX to the sinotubular junction through Guidezilla (Figures 2(d) and 2(e)). The flow of the right coronary artery and circumflex was retained, and the elevated ST segment in the EKG was reversed (Figure 2(f)). The patient tolerated the procedure well without complications, recovered uneventfully, and was discharged 7 days after the procedure without complications. At the 30-day follow-up, he had notable improvement of symptoms and physical activity, with a change to NYHA class I from class III. Six months after being discharged from our hospital, CTA of coronary artery suggested unobstructed coronary flow of the CX (Figures 3(b)–3(d)).
Figure 1

Cardiac computed tomography angiography showed severely calcified aortic leaflets with anatomical abnormalities of the right coronary system, which revealed a circumflex branch originating from the right coronary sinus, as shown by CAG.

Figure 2

Balloon aortic valvuloplasty and simultaneous aortic root injection showing decreased coronary flow to TIMI-0 in the RCA and CX. One guidewire was advanced to the RCA and CX with a 2.0∗20 mm semicompliant balloon. There was flow compromise in the right coronary system and CX to TIMI-0 flow after TAVR, followed by deployment of two stents from the proximal CX branch to the sinotubular junction. The flow of the right coronary artery and CX was retained, and the elevated ST segment in the EKG was reversed.

Figure 3

Six-month follow-up results after TAVR. (a) Cardiac computed tomography angiography showed a circumflex branch originating from right coronary sinus before TAVR. (b–d) Six-month follow-up after TAVR. CTA of the aortic and coronary regions suggested unobstructed coronary flow of the CX.

3. Discussion

TAVR is an acceptable and effective alternative to SAVR in high-risk or intermediate-risk patients. However, a rare but devastating complication is coronary ostial obstruction during the TAVR procedure. There are some key predictors of CAO, including low coronary ostia, inadequate SOV width, and, in the context of VIV procedures, surgical bioprostheses with externally mounted leaflets or a short virtual transcatheter valve-to-coronary ostium (VTC) distance [6, 7]. An anomalous coronary artery can be a predictor of CAO. In some special patients at high risk of CAO during TAVR procedure, upfront coronary artery protection can be provided by positioning a coronary guidewire, balloon, undeployed stent, or guide extension in the artery [8, 9]. Recent research has reported that chimney stenting is infrequently performed in modern TAVR practice (approximately 0.5% of overall TAVR cases), and this technique is not only performed for the acute treatment of total occlusion of coronary flow but also applied when imaging reveals partial obstruction of the coronary ostium or reduced coronary blood flow and an evolution to complete CAO is anticipated [5]. Thorough evaluation of each case prior to TAVR using coronary angiography, CT scanning, and echocardiography enabled us to identify patients we believed to be at increased risk for coronary compromise during the TAVR procedure. The utilization of the chimney stenting protection method helped in the early diagnosis and efficient treatment of coronary compromise during TAVR. The stent is retracted to extend from the proximal portion of the coronary artery cranially, exteriorly, and parallel to the transcatheter heart valve and is deployed to create a channel for coronary perfusion between the displaced leaflets and the aortic wall. In this case, we successfully performed coronary protection by using the chimney stenting technique in anatomical abnormalities of the circumflex system, which originated from the right SOV. When the ostium of the right coronary artery and circumflex artery were occluded by calcified valve cusps, we rapidly planted 2 stents from the proximal CX branch to the sinotubular junction and created a channel for coronary perfusion between the displaced leaflets and the aortic wall; hence, the coronary flow was maintained. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a transcatheter procedure performed immediately before TAVR at high risk of coronary artery obstruction, in which the target aortic native or bioprosthetic leaflets are split using focused radiofrequency energy directed by catheters and guide wires [10]. One-year outcome of the BASILICA trial reveals that there was no late stroke, myocardial infarction, or death related to BASILICA, and the mitigation of coronary obstruction remained intact at 1 year, thereby, the BASILICA technique could avoid the long-term complications related to snorkel stenting [11]. In our case, pre-TAVR cardiac CT imaging suggested a relatively high risk for coronary obstruction in right SOV; therefore, it could be a good alternative to perform BASILICA technique before TAVR.

4. Conclusions

Chimney stenting protection as a bailout technique is safe and feasible and should be considered in patients deemed to be at high risk of coronary flow compromise, especially with an anomalous LCX.
  11 in total

1.  Clinical impact of coronary protection during transcatheter aortic valve implantation: first reported series of patients.

Authors:  Yigal Abramowitz; Tarun Chakravarty; Hasan Jilaihawi; Mohammad Kashif; Yoshio Kazuno; Nobuyuki Takahashi; Yoshio Maeno; Mamoo Nakamura; Wen Cheng; Raj R Makkar
Journal:  EuroIntervention       Date:  2015-09       Impact factor: 6.534

Review 2.  Coronary obstruction in transcatheter aortic valve-in-valve implantation: preprocedural evaluation, device selection, protection, and treatment.

Authors:  Danny Dvir; Jonathon Leipsic; Philipp Blanke; Henrique B Ribeiro; Ran Kornowski; Augusto Pichard; Joseph Rodés-Cabau; David A Wood; Dion Stub; Itsik Ben-Dor; Gabriel Maluenda; Raj R Makkar; John G Webb
Journal:  Circ Cardiovasc Interv       Date:  2015-01       Impact factor: 6.546

3.  Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry.

Authors:  Danny Dvir; John Webb; Stephen Brecker; Sabine Bleiziffer; David Hildick-Smith; Antonio Colombo; Fleur Descoutures; Christian Hengstenberg; Neil E Moat; Raffi Bekeredjian; Massimo Napodano; Luca Testa; Thierry Lefevre; Victor Guetta; Henrik Nissen; José-María Hernández; David Roy; Rui C Teles; Amit Segev; Nicolas Dumonteil; Claudia Fiorina; Michael Gotzmann; Didier Tchetche; Mohamed Abdel-Wahab; Federico De Marco; Andreas Baumbach; Jean-Claude Laborde; Ran Kornowski
Journal:  Circulation       Date:  2012-10-10       Impact factor: 29.690

4.  The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction.

Authors:  Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Toby Rogers; Marvin H Eng; Gaetano Paone; Bradley G Leshnower; Mark Reisman; Lowell Satler; Ron Waksman; Marcus Y Chen; Annette M Stine; Xin Tian; Danny Dvir; Robert J Lederman
Journal:  JACC Cardiovasc Interv       Date:  2019-06-12       Impact factor: 11.195

5.  Transcatheter aortic valve implantation in the presence of an anomalous left circumflex coronary artery: a case report.

Authors:  Mackenzie Mbai; Alok Sharma; Brett Oestreich; Asher Sobotka; Rosemary F Kelly; Horst Sievert; Stefan Bertog
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

6.  Impact of preparatory coronary protection in patients at high anatomical risk of acute coronary obstruction during transcatheter aortic valve implantation.

Authors:  Masanori Yamamoto; Tetsuro Shimura; Seiji Kano; Ai Kagase; Atsuko Kodama; Yutaka Koyama; Yusuke Watanabe; Norio Tada; Kensuke Takagi; Motoharu Araki; Shinichi Shirai; Kentaro Hayashida
Journal:  Int J Cardiol       Date:  2016-05-04       Impact factor: 4.164

Review 7.  Coronary obstruction following transcatheter aortic valve implantation: a systematic review.

Authors:  Henrique Barbosa Ribeiro; Luis Nombela-Franco; Marina Urena; Michael Mok; Sergio Pasian; Daniel Doyle; Robert DeLarochellière; Mélanie Côté; Louis Laflamme; Hugo DeLarochellière; Ricardo Allende; Eric Dumont; Josep Rodés-Cabau
Journal:  JACC Cardiovasc Interv       Date:  2013-04-17       Impact factor: 11.195

8.  Chimney Stenting for Coronary Occlusion During TAVR: Insights From the Chimney Registry.

Authors:  Federico Mercanti; Liesbeth Rosseel; Antoinette Neylon; Rodrigo Bagur; Jan-Malte Sinning; Georg Nickenig; Eberhard Grube; David Hildick-Smith; Davide Tavano; Alexander Wolf; Giuseppe Colonna; Azeem Latib; Satoru Mitomo; Anna Sonia Petronio; Marco Angelillis; Didier Tchétché; Chiara De Biase; Marianna Adamo; Mohammed Nejjari; Franck Digne; Ulrich Schäfer; Nicolas Amabile; Guy Achkouty; Raj R Makkar; Sung-Han Yoon; Ariel Finkelstein; Danny Dvir; Tara Jones; Bernard Chevalier; Thierry Lefevre; Nicolo Piazza; Darren Mylotte
Journal:  JACC Cardiovasc Interv       Date:  2020-03-23       Impact factor: 11.195

9.  Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry.

Authors:  Henrique B Ribeiro; Josep Rodés-Cabau; Philipp Blanke; Jonathon Leipsic; Jong Kwan Park; Vinayak Bapat; Raj Makkar; Matheus Simonato; Marco Barbanti; Joachim Schofer; Sabine Bleiziffer; Azeem Latib; David Hildick-Smith; Patrizia Presbitero; Stephan Windecker; Massimo Napodano; Alfredo G Cerillo; Mohamed Abdel-Wahab; Didier Tchetche; Claudia Fiorina; Jan-Malte Sinning; Mauricio G Cohen; Mayra E Guerrero; Brian Whisenant; Fabian Nietlispach; José Honório Palma; Luis Nombela-Franco; Arend de Weger; Malek Kass; Fabio Sandoli de Brito; Pedro A Lemos; Ran Kornowski; John Webb; Danny Dvir
Journal:  Eur Heart J       Date:  2018-02-21       Impact factor: 29.983

10.  BASILICA Trial: One-Year Outcomes of Transcatheter Electrosurgical Leaflet Laceration to Prevent TAVR Coronary Obstruction.

Authors:  Jaffar M Khan; Adam B Greenbaum; Vasilis C Babaliaros; Danny Dvir; Mark Reisman; James M McCabe; Lowell Satler; Ron Waksman; Marvin H Eng; Gaetano Paone; Marcus Y Chen; Christopher G Bruce; Annette M Stine; Xin Tian; Toby Rogers; Robert J Lederman
Journal:  Circ Cardiovasc Interv       Date:  2021-05-18       Impact factor: 6.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.